Segall Bryant & Hamill LLC Has $27.93 Million Holdings in NeoGenomics, Inc. (NASDAQ:NEO)

Segall Bryant & Hamill LLC lifted its holdings in shares of NeoGenomics, Inc. (NASDAQ:NEO) by 67.0% during the 3rd quarter, Holdings Channel reports. The firm owned 1,893,407 shares of the medical research company’s stock after purchasing an additional 759,524 shares during the period. Segall Bryant & Hamill LLC’s holdings in NeoGenomics were worth $27,928,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Bellevue Group AG bought a new stake in NeoGenomics during the first quarter worth about $14,872,000. Kopp LeRoy C bought a new stake in shares of NeoGenomics during the 1st quarter worth approximately $14,062,000. First Light Asset Management LLC lifted its holdings in shares of NeoGenomics by 14.5% during the 2nd quarter. First Light Asset Management LLC now owns 3,782,561 shares of the medical research company’s stock worth $52,464,000 after acquiring an additional 480,396 shares during the period. Dimensional Fund Advisors LP boosted its position in shares of NeoGenomics by 7.0% during the 2nd quarter. Dimensional Fund Advisors LP now owns 3,324,624 shares of the medical research company’s stock worth $46,108,000 after acquiring an additional 217,687 shares in the last quarter. Finally, American Century Companies Inc. increased its stake in NeoGenomics by 5.4% in the second quarter. American Century Companies Inc. now owns 3,261,756 shares of the medical research company’s stock valued at $45,241,000 after acquiring an additional 167,145 shares during the last quarter. 98.50% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other NeoGenomics news, General Counsel Alicia C. Olivo sold 5,175 shares of NeoGenomics stock in a transaction dated Friday, November 15th. The stock was sold at an average price of $15.36, for a total transaction of $79,488.00. Following the transaction, the general counsel now directly owns 37,129 shares of the company’s stock, valued at approximately $570,301.44. The trade was a 12.23 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 1.30% of the company’s stock.

NeoGenomics Trading Up 2.3 %

Shares of NEO stock opened at $15.36 on Wednesday. NeoGenomics, Inc. has a twelve month low of $12.77 and a twelve month high of $21.22. The stock’s fifty day simple moving average is $14.67 and its 200 day simple moving average is $14.82. The company has a quick ratio of 1.91, a current ratio of 1.99 and a debt-to-equity ratio of 0.37. The firm has a market capitalization of $1.97 billion, a P/E ratio of -24.61 and a beta of 1.19.

NeoGenomics (NASDAQ:NEO) last released its quarterly earnings results on Tuesday, November 5th. The medical research company reported $0.05 earnings per share for the quarter, topping the consensus estimate of $0.01 by $0.04. The company had revenue of $167.80 million for the quarter, compared to analysts’ expectations of $167.00 million. NeoGenomics had a negative return on equity of 2.11% and a negative net margin of 12.07%. The business’s quarterly revenue was up 10.5% compared to the same quarter last year. During the same period in the previous year, the business posted ($0.06) earnings per share. As a group, sell-side analysts predict that NeoGenomics, Inc. will post -0.17 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts have weighed in on NEO shares. Benchmark restated a “buy” rating and set a $18.00 target price on shares of NeoGenomics in a research note on Tuesday, September 24th. Needham & Company LLC restated a “buy” rating and set a $19.00 price objective on shares of NeoGenomics in a research report on Wednesday, November 6th. Finally, Stephens reiterated an “overweight” rating and issued a $19.00 target price on shares of NeoGenomics in a research report on Tuesday, July 30th. Nine equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus price target of $20.25.

NeoGenomics Profile

NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.